Topic 13 — Lung and Laryngeal Neoplasms

Connect the major pathological and clinical relationships for rapid KMU-focused revision.

1. THE TOPIC IN ONE CONNECTED FLOW

Lung and laryngeal neoplasms are best understood by linking exposure or tumour origin with malignant transformation, characteristic morphology, local structural effects and clinical presentation. The main distinction is between aggressive lung carcinomas, lower-grade bronchial neuroendocrine tumours, pleural mesothelioma and laryngeal squamous malignancy.

Risk / Origin
Smoking, asbestos or neoplastic epithelial change

→

Cellular Change
DNA injury and abnormal clonal proliferation

→

Morphology
Glands, keratin, small cells, neuroendocrine nests or pleural rind

→

Structural Effect
Bronchial obstruction, pleural restriction or altered vocal-cord function

→

Presentation
Cough, hemoptysis, dyspnea, pleural pain or hoarseness

→

Diagnosis / Management
Histology defines type; treatment follows tumour biology and extent

Main biological branch:

SCLC → rapid growth → early dissemination → systemic treatment emphasis

NSCLC → comparatively more localized course in selected cases → possible surgical resection

2. KEY CLINICAL CONNECTIONS

Lung tumour morphology → behaviour

Small cells + numerous mitoses + necrosis
→
highly aggressive neuroendocrine carcinoma
→
early metastatic spread.

Gland formation or keratinization
→
NSCLC subtype identification
→
different biological and treatment implications.

Endobronchial carcinoid → local symptoms

Central vascular tumour
→
bronchial narrowing
→
recurrent distal infection or collapse.

High vascularity
→
airway bleeding
→
hemoptysis.

Asbestos → mesothelioma

Fibre deposition near pleura
→
chronic mesothelial injury
→
diffuse pleural malignancy.

Pleural rind and effusion
→
restricted lung expansion
→
progressive dyspnea.

Laryngeal site → presentation and action

True vocal-cord lesion
→
disturbed vibration
→
early persistent hoarseness.

Progressive airway narrowing
→
stridor
→
urgent airway assessment.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Smoking → repeated epithelial DNA injury → lung carcinoma; the association is especially strong with squamous and small-cell carcinoma.

Peripheral gland formation or mucin → adenocarcinoma; this subtype is also important in patients who have never smoked.

⭐ Small-cell morphology → high-grade neuroendocrine behaviour → early dissemination; this explains why surgery is generally not the main treatment strategy.

Uniform neuroendocrine cells with low proliferative activity → bronchial carcinoid; central growth then explains obstruction, recurrent pneumonia and hemoptysis.

⭐ Asbestos exposure → mesothelial injury → diffuse pleural tumour; coalescing pleural nodules form a rind that restricts lung expansion.

Lung tumour location → clinical effect; central airway involvement causes obstruction and hemoptysis, while invasion of pleura or chest wall contributes to pain.

⭐ Glottic tumour → impaired vocal-cord vibration → early hoarseness; persistent voice change therefore requires laryngeal visualization and tissue confirmation.

Laryngeal tumour extent → treatment choice; localized disease may allow selected surgery or radiotherapy, while airway compromise requires urgent assessment before definitive cancer therapy.

AIM Exam Trap:
Asbestos is strongly linked to malignant mesothelioma, but cigarette smoking is not its major cause. Smoking remains a major risk factor for bronchogenic carcinoma.

Topic 13 — Lung and Laryngeal Neoplasms

1. THE TOPIC IN ONE CONNECTED FLOW

2. KEY CLINICAL CONNECTIONS

3. AIM HIGH-YIELD INTEGRATION REVIEW

Install AIM App